Viking Therapeutics, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Brian Lian
- Full Time Employees
- 53
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 9920 Pacific Heights Boulevard San Diego CA United States 92121
- IPO Date
- Apr 28, 2015
- CIK
- 0001607678
- Website
- vikingtherapeutics.com
- Similar Companies
- Business
- Viking Therapeutics, Inc. (NASDAQ: VKTX) is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for metabolic and endocrine disorders. Founded in 2012 and headquartered in San Diego, California, the company advances a pipeline targeting obesity, metabolic dysfunction-associated steatohepatitis (MASH), non-alcoholic fatty liver disease (NAFLD), lipid disorders, and rare diseases such as X-linked adrenoleukodystrophy (X-ALD). Its core programs include VK2735, a dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist available in subcutaneous and oral formulations for obesity and related metabolic conditions; VK2809, an orally available small molecule selective thyroid hormone receptor beta (TR beta) agonist for MASH, fibrosis, NAFLD, and elevated low-density lipoprotein cholesterol (LDL-C); dual amylin and calcitonin receptor agonists (DACRAs) for obesity; and VK0214, an orally available selective TR beta agonist for X-ALD. Viking Therapeutics operates primarily in the United States with a focus on patients suffering from high unmet needs in metabolic and endocrine diseases, leveraging internal expertise in metabolism to drive innovation across its wholly-owned pipeline. The company's lead candidate, subcutaneous VK2735, advances in Phase 3 VANQUISH-1 and VANQUISH-2 registration trials for obesity in adults with and without type 2 diabetes, following positive Phase 2 VENTURE trial results; the oral formulation of VK2735 progresses in the Phase 2 VENTURE-Oral trial, with enrollment completed and data anticipated in the second half of 2025. VK2809 met primary and secondary endpoints in the Phase 2b VOYAGE trial for biopsy-confirmed MASH and fibrosis, building on prior Phase 2a data showing significant LDL-C and liver fat reductions; VK0214 demonstrated proof-of-concept in a Phase 1b trial for X-ALD by reducing very long-chain fatty acids. Recent developments include the completion of enrollment in the Phase 3 VANQUISH-1 trial for subcutaneous VK2735 in November 2025, alongside plans for a Phase 1 monthly dosing study in the third or fourth quarter of 2025 and an investigational new drug (IND) filing for its amylin agonist program in the fourth quarter of 2025. In March 2025, Viking secured a $150 million multi-year manufacturing agreement with CordenPharma to produce multiple metric tonnes of VK2735 annually, supporting over one billion oral pills or substantial injectable volumes to meet potential commercial demand. Phase 3 trials for subcutaneous VK2735 commenced in the second quarter of 2025, positioning the company to compete in the expanding obesity market dominated by GLP-1-based therapies.
Company News
Here's the 1 Stock I'd Most Want to Buy If the Market Crashes
Viking Therapeutics Trades 23% Below Its Own $35 Secondary Offering Price. Here's Why That Could Be a Gift for Patient Investors.
How I'd Invest $10,000 Right Now
Viking Therapeutics to Participate at Upcoming Investor Conferences
UBS Just Initiated Coverage of Viking Therapeutics With a Buy Rating and a $94 Target. Here's the Bull Case.
VKTX: Is a 2029 Launch for Its Obesity Drug Within Reach?
Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet
Viking Therapeutics: Q3 Update - Why You Can't Discount This GLP-1 Player (Yet)
VKTX Q3 Earnings Miss Estimates Amid Rising Clinical Expenses
VKTX Q3 Earnings Call Highlights Obesity Pipeline Progress
Eli Lilly Jumps 8% as Strong Quarter Lifts Revenue Outlook; Novo Nordisk Ticks Up, Viking Therapeutics Eases
Viking Therapeutics: Why A Successful Maintenance Readout Couldn't Save The Stock
Viking Therapeutics Q3 Earnings Call Highlights
Viking Therapeutics, Inc. (VKTX) Q3 2026 Earnings Call Transcript
Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Should You Buy Viking Therapeutics Stock Ahead of Q3 Results?
Why Viking Therapeutics' Oral Obesity Strategy Will Be a Make-or-Break Focus on Oct. 28
Here's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader Market
Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know
NVO vs. VKTX: Which Obesity Stock Could Deliver Bigger Gains?